Farcast reveals novel and actionable insights like no other platform can.

Our technology uses fresh human tumors and autologous blood samples cultured in a proprietary system that preserves the tumor microenvironment. By maintaining the actual tumor architecture and immune cell compartment, Farcast’s ex vivo evaluation of tumor response to drug treatment portrays what happens in vivo.

Preserving tumor fragment heterogeneity across multiple tumor indications.

Tumor cell and stromal components in breast cancer and colorectal cancer samples

breast cancer

colorectal cancer

H&E staining of representative tumor fragments (20X magnification)

A technology poised to reveal drug-specific impact on a patient's own tumor cells.

Characterization of proliferative and apoptotic states in tumor fragments cultured in the Farcast platform.

Proliferative cells

breast cancer

colorectal cancer

Apoptotic cells

breast cancer

colorectal cancer

Immunohistochemical staining of representative tumor fragments (20X magnification). Left, Ki67; right, active caspase-3.

The power to profile tumor response to immuno-oncology therapies.

An intact human tumor microenvironment and immune compartment are essential to accurately evaluate therapies that engage the immune system, making Farcast the optimal choice for gleaning insights into immuno-oncology therapies. The dynamic nature of our human platform enables tracking of critical biological elements such as infiltration of CD8+ cytotoxic T-cells or natural killer cells into the tumor.

11选5稳赚1元